Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

Pankit Vachhani, MD, Craig Freyer, PharmD, BCOP, Jeffrey Baron, PharmD, BCOP, Austin Miller, PhD, Meir Wetzler, MD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 5052.

https://doi.org/10.1182/blood.V130.Suppl_1.5052.5052

Published: 2017

Journal Articles

p38α Activates Purine Metabolism to Initiate Hematopoietic Stem Cell Cycling

Daiki Karigane, MD, Shinichiro Okamoto, Toshio Suda, MD PhD, Keiyo Takubo, MD PhD

Blood (2015) 126 (23): 776.

https://doi.org/10.1182/blood.V126.23.776.776

Published: 2015

Journal Articles

Concomitant Usage of Rasburicase and Allopurinol May Augment Toxic Epidermal Necrolysis Syndrome TEN

Ahmad Jajeh, MD, MPH

Blood (2010) 116 (21): 4949.

https://doi.org/10.1182/blood.V116.21.4949.4949

Published: 2010

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Pharmacokinetics of Intravenous Uricase-PEG 20, a Drug for Managing Hyperuricemia in Tumor Lysis Syndrome.

Zhihua Zhang, MD, PhD, Anthony Fiorino, MD, PhD

Blood (2009) 114 (22): 3086.

https://doi.org/10.1182/blood.V114.22.3086.3086

Published: 2009

Journal Articles

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Doris Ponce, MD, Delong Liu, MD, PhD, Muhammad Rasul, MD, Nasir Ahmed, MD, Marie Dimicco, PhD, Karen Seiter, MD

Blood (2008) 112 (11): 4012.

https://doi.org/10.1182/blood.V112.11.4012.4012

Published: 2008

Journal Articles

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

Jorge Cortes, MD, Karen Seiter, MD, Richard Thomas Maziarz, MD, Meir Wetzler, MD, Michael Craig, MD, Jeffrey Matous, Selina Luger, MD, Bimalangshu Dey, MD, Gary J. Schiller, MD, FACP, Dat Pham, MD, Camille N. Abboud, MD, FACP, Muthuswamy Krishnamurthy, MD, Archie Brown, Jr., MD, Joseph O. Moore, MD

Blood (2008) 112 (11): 919.

https://doi.org/10.1182/blood.V112.11.919.919

Published: 2008

Journal Articles

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Yves Bertrand, Anne Auvrignon, MD, Brigitte Nelken, MD, Valérie Mialoux, MD, Francoise Mechinaud, MD, Catherine Patte, MD, Dominique Plantaz, MD, Nathalie Le Guyader, MD, Marisol Urbieta, MD, Yves Perel, Andre Baruchel9, Guy Leverger

Blood (2005) 106 (11): 3122.

https://doi.org/10.1182/blood.V106.11.3122.3122

Published: 2005

Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

S. Trifilio, A. Evens, L. Gordon, S. Singhal, M. Tallman, J. Mehta

Blood (2005) 106 (11): 3123.

https://doi.org/10.1182/blood.V106.11.3123.3123

Published: 2005

Journal Articles

Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.

Y. Bertrand, A. Auvrignon, B. Nelken, V. Mialou, F. Mechinaud, B. Brethon, C. Patte, D. Plantaz, M. Urbieta, A. Baruchel, G. Leverger

Blood (2004) 104 (11): 5295.

https://doi.org/10.1182/blood.V104.11.5295.5295

Published: 2004

Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

S. Trifilio, M. Tallman, S. Singhal, L. Gordon, A. Evens, J. Mehta

Blood (2004) 104 (11): 3312.

https://doi.org/10.1182/blood.V104.11.3312.3312

Published: 2004

NARROW

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

p38α Activates Purine Metabolism to Initiate Hematopoietic Stem Cell Cycling

Concomitant Usage of Rasburicase and Allopurinol May Augment Toxic Epidermal Necrolysis Syndrome TEN

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Pharmacokinetics of Intravenous Uricase-PEG 20, a Drug for Managing Hyperuricemia in Tumor Lysis Syndrome.

Rasburicase Effectively Lowers Serum Uric Acid Levels in High Risk, Poor Performance Status Patients with Hematologic Malignancies

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only